Citation Impact
Citing Papers
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Actin retrograde flow actively aligns and orients ligand-engaged integrins in focal adhesions
2017 StandoutNobel
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
2014
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2014
Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer
2021
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Breast cancer
2019 Standout
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
2011
Effects of the Change in Cutoff Values for Human Epidermal Growth Factor Receptor 2 Status by Immunohistochemistry and Fluorescence In Situ Hybridization: A Study Comparing Conventional Brightfield Microscopy, Image Analysis-Assisted Microscopy, and Interobserver Variation
2011
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
2015
Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer Therapy
2012
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
2001
Breast cancer
2016 Standout
Targeted Therapy for Breast Cancer
2013
The cancer glycocalyx mechanically primes integrin-mediated growth and survival
2014 StandoutNatureNobel
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
2012
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
2013
The prognostic significance of lymphovascular invasion in invasive breast carcinoma
2011
The biology and function of fibroblasts in cancer
2016 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Significance of histopatholoaical evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response(pCR) as endpoint
2004
Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification: Table 1
2011
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer
2010
Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy
2002
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
2015
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
High-performance medicine: the convergence of human and artificial intelligence
2018 Standout
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
2016 Standout
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
2004
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2013
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
2012
Cell adhesion: integrating cytoskeletal dynamics and cellular tension
2010 Standout
Remodelling the extracellular matrix in development and disease
2014 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
Emerging Biological Principles of Metastasis
2017 Standout
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
2012 Standout
Reporting clinical research: Guidance to encourage accurate and transparent research reporting
2012
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
2014
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
2014
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
2004
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
2011
Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy
2015
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Personalized survival predictions via Trees of Predictors: An application to cardiac transplantation
2018
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival
2003
18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques
2011
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Emerging targeted agents in metastatic breast cancer
2013
Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes
2002
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
2009
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome
2007
Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study
2011
Head and Neck Cancer
2020 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
2003
Neoadjuvant chemotherapy for breast carcinoma
2003
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
2010
The extracellular matrix: A dynamic niche in cancer progression
2012 Standout
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
2011 StandoutNobel
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
2005 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Breast Cancer Treatment
2019 Standout
Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
2012
Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial
2011
Early Depressive Symptoms in Cancer Patients Receiving Interleukin 2 and/or Interferon Alfa-2b Therapy
2000
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
2009
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors
2004
A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer
2020
Near‐Infrared‐Light‐Activatable Nanomaterial‐Mediated Phototheranostic Nanomedicines: An Emerging Paradigm for Cancer Treatment
2018
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
2014
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Primary Systemic Therapy of Breast Cancer
2006
Works of Marc Debled being referenced
Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer
2012
Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial
2001
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
2007
Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations
2008
Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial
2010
Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer
2010
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
2012
Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors
2017
Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
2019
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up
1999
Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death
2010
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
2015
Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women
2002
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
2013
Is it useful to detect lymphovascular invasion in lymph node‐positive patients with primary operable breast cancer?
2010
Present achievements in the medical treatment of metastatic renal cell carcinoma
1999
Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers
2015
Quality of Randomized Controlled Trials Reporting in the Treatment of Sarcomas
2011
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
2017
Final results of the RAPP-01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high-risk node negative and limited node positive (≤3) breast cancer patients.
2009
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
2012